A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets After Oral Administration in Adult Subjects With Binge Eating Disorder
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Centanafadine (Primary)
- Indications Binge-eating disorder
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 29 Sep 2022 Status changed from active, no longer recruiting to completed.
- 26 Jul 2022 Planned End Date changed from 1 Aug 2022 to 5 Sep 2022.
- 26 Jul 2022 Planned primary completion date changed from 25 Jul 2022 to 30 Aug 2022.